# EDGAR Filing Document

**Accession Number:** 0001297184
**File Stem:** 0001297184-26-000013
**Filing Date:** 2026-3
**Character Count:** 69344
**Document Hash:** 9aca7f2900160b460e0faf306941ad19
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001297184-26-000013.hdr.sgml**: 20260306

**ACCESSION NUMBER**: 0001297184-26-000013

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260303

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260306

**DATE AS OF CHANGE**: 20260306

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Amphastar Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001297184
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 330702205
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36509
- **FILM NUMBER:** 26731112

**BUSINESS ADDRESS:**
- **STREET 1:** 11570 SIXTH STREET
- **CITY:** RANCHO CUCAMONGA
- **STATE:** CA
- **ZIP:** 91730
- **BUSINESS PHONE:** 909-980-9484

**MAIL ADDRESS:**
- **STREET 1:** 11570 SIXTH STREET
- **CITY:** RANCHO CUCAMONGA
- **STATE:** CA
- **ZIP:** 91730

?xml version='1.0' encoding='ASCII'? Amphastar Pharmaceuticals, Inc._March 3, 2026

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event Reported): March 3, 2026

**Amphastar Pharmaceuticals, Inc.**

(Exact Name of Registrant as Specified in Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-36509** | **33-0702205** |
| (State or Other Jurisdiction of<br>Incorporation) | (Commission File Number) | (I.R.S. Employer Identification<br>Number) |

---

---

| | |
|:---|:---|
| **11570 6th Street** |  |
| **Rancho Cucamonga, California** | **91730** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **(909) 980-9484**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| T<br>|  |  |
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $0.0001 per share | AMPH | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 1.01.** **Entry into Material Definitive Agreement and Amendment of a Material Definitive Agreement.** 

*Supply Agreement.*

On March 3, 2026, (the "Effective Date"), Amphastar Nanjing Pharmaceuticals, Inc. ("ANP"), the Chinese subsidiary of Amphastar Pharmaceuticals, Inc. ("Amphastar" or, the "Company"), entered into a supply agreement (the "Supply Agreement") with Nanjing Letop Biotechnology Co., Ltd. ("Letop"). Pursuant to the Supply Agreement, Letop will manufacture and deliver chemical intermediates ("Intermediates") for ANP according to the requirements of the purchase orders confirmed by Letop (collectively, the "Transaction"). ANP is entitled to decide the quantity of the Intermediates that it purchases from Letop at its own discretion, and ANP has no obligation to purchase any minimum quantity of the Intermediates from Letop. ANP will retain ownership of all confidential information ANP shares with Letop during the term of this Supply Agreement. Each of ANP and Letop have made customary representations, warranties and covenants in the Supply Agreement. This Supply Agreement will remain in full force and effect for a period of five (5) years from the Effective Date. Payments under the Supply Agreement will be made in Chinese yuan. The Company does not consider this Supply Agreement to be material to its financial condition or results of operations.

As previously disclosed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the Securities Exchange Commission ("SEC") on February 26, 2026, Henry Zhang is an immediate family member of Dr. Jack Zhang, Chief Executive Officer, President, and Director of the Company, Dr. Mary Luo, Chairman, Chief Operating Officer, and Director of the Company. Henry Zhang beneficially owns a majority of the equity interest in Letop, and the Agreement with Letop represents a related party transaction. Accordingly, the members of the Audit Committee of the Board of Directors of the Company evaluated and approved the Transaction and entry into the Agreement following their review of applicable considerations.

The foregoing is a brief description of the material terms of the Supply Agreement, does not purport to be a complete description of the rights and obligations of the parties thereunder, and is qualified in its entirety by reference to the copies of the Supply Agreement, a copy of which is filed as Exhibit 10.1 hereto and incorporated herein by reference.

*Contract Research Amendment*

On March 3, 2026 (the "Effective Date"), Amphastar Pharmaceuticals, Inc ("Amphastar" or, the "Company") and Nanjing Hanxin Pharmaceutical Technology Co., Ltd. ("Hanxin") entered into an amendment (the "Contract Research Amendment") to the Contract Research Agreement (the "Contract Research Agreement"), originally entered into on September 15, 2025, as previously reported by the Company on a Current Report on Form 8-K filed on September 18, 2025.

Pursuant to the Contract Research Amendment, the Company will use the Research Cell Banks (the "RCBs") that Hanxin develops to make Master Cell Banks for product candidates AMP-105, instead of AMP-107 as originally contemplated in the Contract Research Agreement. The total cost of the Contract Research Agreement will be increased by approximately $0.6 million, which reflects the additional work that Hanxin need to perform and compensation to Hanxin for the work already provided for AMP-107. The Company does not consider this Contract Research Amendment to be material to its financial condition or results of operations.

As previously disclosed in the Definitive Proxy Statement for the Company's 2025 Annual Meeting of Stockholders, as filed with the SEC on Schedule 14A on April 14, 2025, Dr. Jack Zhang, the Company's Chief Executive Officer, President, and Director; and Dr. Mary Luo, the Company's Chairman, Chief Operating Officer, and Director; and certain members of their family beneficially own a majority of the equity interest in Hanxin, Henry Zhang, the son of Dr. Jack Zhang, is also the general manager, and the chairman of the board of directors of Hanxin. The Audit Committee of the Board of Directors of the Company evaluated and approved entry into the Contract Research Amendment following review of applicable considerations.

The foregoing is a brief description of the Contract Research Amendment, does not purport to be a complete description of the rights and obligations of the parties thereunder, and is qualified in their entirety by reference to the copy of the Contract Research Amendment, a copy of which is filed as Exhibit 10.2 hereto and incorporated herein by reference.

Forward-Looking Statements

All statements in this current report that are not historical are forward-looking statements, including, among other things, statements relating to the performance of the parties under the Agreement and the expected payments thereunder. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may,"

"might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including changes in laws and regulations and disruptions in supply chains as well as others described in Amphastar's filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 26, 2026 and in our other filings or reports that we may file with the SEC. You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this current report speak only as of the date of the report. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this current report to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.

**Item 9.01. Financial Statements and Exhibits**

**(d) Exhibits**

---

| | |
|:---|:---|
| Exhibit<br>No. | Description |
| 10.1\* | [Supply Agreement by and between Amphastar Nanjing Pharmaceuticals, Inc. and Nanjing Letop Biotechnology Co., Ltd., dated March 3, 2026](amph-20260303xex10d1.htm) |
| 10.2\* | [First Amendment to the Contract Research Agreement by and between Amphastar Pharmaceuticals, Inc. and Nanjing Hanxin Pharmaceutical Technology Co., Ltd., dated March 3, 2026](amph-20260303xex10d2.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

\* Certain confidential information contained in this Exhibit was omitted by means of marking such portions with brackets because the identified confidential information (i) is not material and (ii) would be competitively harmful if publicly disclosed.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | AMPHASTAR PHARMACEUTICALS, INC. | AMPHASTAR PHARMACEUTICALS, INC. |
| Date: March 6, 2026 |  |  |
|  | By: | **/S/WILLIAM J. PETERS** |
|  |  | William J. Peters |
|  |  | Chief Financial Officer, Executive Vice President and Treasurer |

---

## Exhibit 10.1

**Exhibit 10.1**

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([\*\*\*]), HAS BEEN OMITTED PURSUANT TO ITEM 601(B)(10)(IV) OF REGULATION S-K, BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. IN ADDITION, CERTAIN SCHEDULES (OR SIMILAR ATTACHMENTS) HAVE BEEN OMITTED FROM THIS EXHIBIT PURSUANT TO ITEM 601(A)(5) OF REGULATION S-K.

Agreement No.: ANP202603001

**SUPPLY AGREEMENT**

**供应协议**

This Supply Agreement (this "**Agreement**") is entered into by and between the following parties on March 3, 2026 (the "**Effective Date**"):

本供应协议（"**本协议**"）由以下双方于 2026年3 月3 日（"**生效日**"）签订：

**(1) Amphastar Nanjing Pharmaceuticals, Inc.**, a limited liability company duly incorporated and validly existing under the laws of PRC, with the unified social credit code: [\*\*\*] (the "**Customer**"); and

&nbsp;&nbsp;&nbsp;&nbsp;**(1)** **美药星（南京）制药有限公司** ， 一家根据中国法律注册并存续的有限责任公司，社会统一信用代码为： [\*\*\*] （ "**买方**" ）；及

**(2) Nanjing Letop Biotechnology Co., Ltd.**, a limited liability company duly incorporated and validly existing under the laws of PRC, with the unified social credit code: [\*\*\*] (the **"Supplier"**).

**(2) 南京乐韬生物科技有限公司**，一家根据中国法律注册并存续的有限责任公司，社会统一信用代码为：[\*\*\*]（"**供应方**"）。

The Supplier and the Customer are sometimes referred to herein collectively as the "**Parties**" and individually as a "**Party**".

本协议项下供应方和买方合称为"**双方**"，单独称为"**一方**"。

**Whereas**, the Customer intends to purchase certain Products (as defined below) which are manufactured by the Supplier in the Territory based on Specifications and formula provided by the Customer, and the Supplier intends to accept such purchase order.

鉴于，买方有意购买供应方根据买方提供的质量标准及规程于区域内生产的特定产品（定义见下文），并且供应方有意接受该等采购订单。

------

Agreement No.: ANP202603001

**Therefore,** based on the principle of good faith, the Parties hereby agree as follows:

因此，双方基于诚实信用原则达成如下约定：

&nbsp;&nbsp;&nbsp;&nbsp;**1.** **General** 

&nbsp;&nbsp;&nbsp;&nbsp;**1.** **总则** 

&nbsp;&nbsp;&nbsp;&nbsp;1.1 Headings or titles of this Agreement are used solely for convenience and shall be given no effect in the construction or interpretation of this Agreement .

&nbsp;&nbsp;&nbsp;&nbsp;1.1 本协议标题仅为方便查阅而设，不影响对本协议的解读或解释。

&nbsp;&nbsp;&nbsp;&nbsp;1.2 Additional agreements necessary to effectuate this Agreement may be executed between the Parties. In the event of conflicting terms, the terms of this Agreement shall prevail.

&nbsp;&nbsp;&nbsp;&nbsp;1.2 双方可以签署为实现本协议所必需的附属协议。如有冲突，则以本协议的约定为准。

&nbsp;&nbsp;&nbsp;&nbsp;1.3 When used in this Agreement, the following terms shall have the meanings set forth in this section:

&nbsp;&nbsp;&nbsp;&nbsp;1.3 本协议中使用的术语含义解释如下：

&nbsp;&nbsp;&nbsp;&nbsp;(a) "**Affiliate**" means any person or entity which controls, is controlled by or is under the common control of a Party. As used in this Agreement, "**control**" means (i) in the case of corporate entities, direct or indirect ownership of at least fifty percent (50%) of the stock or shares having the right to vote for the election of directors, or (ii) in the case of non-corporate entities, the direct or indirect power to manage, direct or cause the direction of the management and policies of the non-corporate entity.

&nbsp;&nbsp;&nbsp;&nbsp;(a) **关联方** ：指控制一方、受一方控制或与一方受共同控制的任何个人或实体。在本协议中， "**控制**" 指 (i) 在 公司 实体中，直接或间接持有该实体不少于百分之五十 （ 50% ） 的有权选举董事的投票权的股权或股份；或 (ii) 在非 公司 实体中，拥有直接或间接参与该实体的管理、决定或指导该实体管理政策的方向的权力。

&nbsp;&nbsp;&nbsp;&nbsp;(b) "**Applicable Law**" means all ordinances, rules, regulations, laws, and requirements of any authority applicable to the Manufacture, supply, use of the Products and/or other activities under this Agreement, as amended from time-to-time, including cGMP.

&nbsp;&nbsp;&nbsp;&nbsp;(b) **适用的法律** ：指不 时 修订的适用于产品的制造、供应 、 使用 和 / 或本协议项下其他活动 的任何监管机构的所有法令、规则、法规、法律和要求，包括 cGMP 。

------

Agreement No.: ANP202603001

&nbsp;&nbsp;&nbsp;&nbsp;(c) "**Confidential Information**" means technical and business information relating to inventions, proprietary ideas and/or patentable ideas, patent applications, background intellectual property, techniques, scientific knowledge, know-how processes, existing and/or contemplated products and services, software, biological material, schematics, research and development, production, costs, profit and margin information, finances and financial projections, customers, clients, licensees, marketing, and current or future business plans and models, regardless of whether such information is designated as "Confidential Information" at the time of disclosure. The term "Confidential Information" does not include such information which:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) is or becomes generally available to the public, other than through the receiving party's disclosure,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) was within the receiving party's possession prior to it being furnished by or on behalf of the disclosing party, provided that receiving party's source had no obligation of confidentiality to the disclosing party,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) becomes available to the receiving party on a non-confidential basis from an information provider other than the disclosing party, provided that the information provider did not have a duty of confidentiality to the disclosing party, or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) is or becomes independently developed by an employee of the receiving party without access to the Confidential Information and without violating any of the receiving party's obligations under this Agreement, as can be demonstrated by the receiving party's written records.

&nbsp;&nbsp;&nbsp;&nbsp;(c) **保密信息** ：指与发明、专有思想和 / 或可转化为专利思想、专利申请、底层知识产权、技术、科学知识、专有技术流程、现有的和 / 或预期的产品和服务、软件、生物材料、示意图、研究和开发、生产、成本及利润信息、财务和财务预测、顾客、客户、被许可方、市场销售以及当前或未来的商业计划和模式有关的技术和商业信息，无论该等信息在披露时是否被指定为 " 保密信息 " 。 " 保密信息 " 不包括以下信息：

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) 在接收方披露前，已是公开或公众普遍可用的，

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) 在披露方提供或代表披露方提供信息之前，接收方已拥有的信息，前提是接收方的信息来源对披露方没有保密义务，

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) 接收方在非保密的基础上已从披露方以外的信息提供方获得的信息，前提是信息提供方对披露方没有保密义务，或

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) 接收方的员工在未接触保密信息且未违反接收方在本协议项下的任何义务的情况下，已独立开发获得的信息，且有接收方的书面记录证明。

------

Agreement No.: ANP202603001

&nbsp;&nbsp;&nbsp;&nbsp;(d) "**Contract Year**" means each consecutive twelve (12) month period during the Term, the first of which shall commence on the Effective Date and shall end on the first anniversary thereof.

&nbsp;&nbsp;&nbsp;&nbsp;(d) **合同年** ：指协议期限内每一连续的十二（ 12 ）个月， 第一个合同年 从 生效日 开始至一周年后结束。

&nbsp;&nbsp;&nbsp;&nbsp;(e) "**Force Majeure**" means an event beyond the reasonable control of a Party including but not limited to, a breakdown of machinery or equipment, fire, flood, sabotage, shipwreck, embargo, strike, explosion, labor trouble, pandemic and related restrictions, accident, riot, act of governmental authority (including without limitation, acts relating to raw material or product allocation, and government drug files), acts of God, acts of war and delays or failures in obtaining materials, supplies, equipment or transportation.

&nbsp;&nbsp;&nbsp;&nbsp;(e) **不可抗力** ：指超出一方合理控制范围的事件，包括但不限于机器或设备损毁、火灾、洪水、破坏、海难、禁运、罢工、爆炸、 罢工 、流行病和相关限制、事故、暴乱，政府当局的行为（包括但不限于与原材料或产品分配有关的行为，以及政府药事文件）、天灾、战争行为以及材料、供应品、设备或运输的延误或损坏。

&nbsp;&nbsp;&nbsp;&nbsp;(f) "**NMPA**" means the National Medical Products Administration and any successor agency having substantially the same functions.

&nbsp;&nbsp;&nbsp;&nbsp;(f) **NMPA** ：指国家药品监督管理局，或具备相同职能的任一下属机构。

&nbsp;&nbsp;&nbsp;&nbsp;(g) "**Manufacture**" and "**Manufacturing**" means any steps, processes and activities necessary to produce the Products, including without limitation, the manufacturing, processing, bulk packaging and labeling, quality control testing, release and storage of the Products.

&nbsp;&nbsp;&nbsp;&nbsp;(g) **生产** ：指产品生产所需的任何步骤、流程及操作，包括但不限于产品的制造、加工、批量包装和贴签、质量控制测试、放行和储存。

&nbsp;&nbsp;&nbsp;&nbsp;(h) "**PRC**" means the People's Republic of China, but solely for the purposes of this Agreement, excluding the Hong Kong Special Administrative Region, the Macau Special Administrative Region and the islands of Taiwan.

&nbsp;&nbsp;&nbsp;&nbsp;(h) **中国** ：指 中华人民 共和国 ， 仅为本协议之目的 ， 不包括香港特别行政区 、 澳门特别行政区和台湾地区。

&nbsp;&nbsp;&nbsp;&nbsp;(i) "**Products**" mean any or all of the products listed in Appendix A hereof.

------

Agreement No.: ANP202603001

&nbsp;&nbsp;&nbsp;&nbsp;(i) **产品** ：指本协议附录 A 中列明 的任一或全部产品 。

&nbsp;&nbsp;&nbsp;&nbsp;(j) "**Regulatory Dossiers**" means all registration, permits, licenses, authorizations, approvals, presentations, notifications or filings (together with all applications therefore), which are filed with or granted by the governing health authority of any country, and which are required to develop, make, use, or sell the Products.

&nbsp;&nbsp;&nbsp;&nbsp;(j) **监管档案** ：指产品的研发、生产、销售及使用所需的，向任一国家的卫生政府部门提交的或由任一国家的卫生政府部门授权的所有注册、许可、执照、授权、批准、介绍、通知或备案文件（及其全部申请材料）。

&nbsp;&nbsp;&nbsp;&nbsp;(k) "**Specifications**" means the specifications set forth in Appendix B hereof, as such specifications may be adjusted from time to time by mutual written consent of the Parties.

&nbsp;&nbsp;&nbsp;&nbsp;(k) **质量标准** ：指本协议附录 B 列明的质量标准，可经由双方共同书面同意不时调整。

&nbsp;&nbsp;&nbsp;&nbsp;(l) "**Term**" means the period during which this Agreement is in effect as set forth in Section 11 .

&nbsp;&nbsp;&nbsp;&nbsp;(l) **协议期限** ：指本协议第 11 条所约定的本协议的生效期限。

&nbsp;&nbsp;&nbsp;&nbsp;(m) "**Territory**" means the PRC.

&nbsp;&nbsp;&nbsp;&nbsp;(m) **区域** ：指中国。

&nbsp;&nbsp;&nbsp;&nbsp;(n) "**Contract Price**" means, with respect to each Product, the Selling Price for each Product as provided in Appendix A, as such Selling Price may be adjusted based on the terms and conditions of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;(n) **合同价格** ：指附录 A 列明的每项产品的销售价格，可 根据本协议的条款和条件 进行调整。

&nbsp;&nbsp;&nbsp;&nbsp;**2.** **T he Customer's Rights and Obligations** 

&nbsp;&nbsp;&nbsp;&nbsp;**2.** **买方权利义务** 

&nbsp;&nbsp;&nbsp;&nbsp;2.1 The Customer shall issue purchase orders to the Supplier. The purchase order shall specify the quantity, standard, expected delivery date and other matters mutually agreed by the Parties. The Parties hereby agree that the Customer shall provide the Supplier with a delivery period of no less than ninety (90) days. T he Supplier shall confirm within ten (10) business days after receipt of the purchase order .

&nbsp;&nbsp;&nbsp;&nbsp;2.1 买方应向 供应方 发出采购订单，采购订单中应明确数量、规格、拟要求交付时间以及其他

------

Agreement No.: ANP202603001

双方共同同意的事项。双方确认，买方应为供应方提供至少九十（90）日的交货周期。供应方应当于收悉买方采购订单后十（10）个工作日内进行确认。

&nbsp;&nbsp;&nbsp;&nbsp;2.2 The Customer is entitled to decide the quantity of Products that it purchases from the Supplier at its own discretion, and the Customer has no obligation to purchase any minimum quantity of Products from the Supplier.

&nbsp;&nbsp;&nbsp;&nbsp;2.2 买方有权自行决定向供应方购买的产品数量，买方无义务向供应方购买任何最低数量产品。

&nbsp;&nbsp;&nbsp;&nbsp;**3.** **The Supplier's Rights and Obligations** 

&nbsp;&nbsp;&nbsp;&nbsp;**3.** **供应方 权利义务** 

&nbsp;&nbsp;&nbsp;&nbsp;3.1 The Supplier shall deliver the Products to the Customer according to the requirements of the purchase orders confirmed by the Supplier, and FCA rules under International Rules for the Interpretation of Trade Terms 2020 (Incoterms 2020) shall apply to such delivery. The Parties hereby agree that the Supplier's additional costs arising from such delivery (including but not limited to, costs for transportation, customs and late receipt of the Customer's designated carrier) shall be borne by the Customer.

&nbsp;&nbsp;&nbsp;&nbsp;3.1 供应方 应根据 供应方 确认的订单要求向买方交付产品，产品交付方式依照《国际贸易术语解释通则（ 2020 年版）》 FCA 术语规则。双方确认， 供应方 因产品交付产生的额外费用成本（包括但不限于运输费用、出口清关费用、买方指定承运人逾期收货费用）应由买方承担。

&nbsp;&nbsp;&nbsp;&nbsp;3.2 The Supplier shall Manufacture and deliver the Products in conformance with the Applicable Law and regulations and Specifications.

&nbsp;&nbsp;&nbsp;&nbsp;3.2 供应方 应依据适用法律、法规及质量标准的相关规定生产和交付产品。

&nbsp;&nbsp;&nbsp;&nbsp;**4.** **Contract Price, Invoice and Payment** 

&nbsp;&nbsp;&nbsp;&nbsp;**4.** **合同 价格、开票及结算** 

&nbsp;&nbsp;&nbsp;&nbsp;4.1 The Supplier shall issue invoices within five (5) business days after shipment, unless the Parties determine that the Products do not conform to the Specifications, payment shall be due thirty (30) days after the date of an invoice from the Supplier.

&nbsp;&nbsp;&nbsp;&nbsp;4.1 供应方 应在发货后五（ 5 ）个工作日内向买方开具发票，除非经由双方确认产品不符合质量标准，买方应在 供应方 开具发票后三十（ 30 ）日内完成付款。

------

Agreement No.: ANP202603001

&nbsp;&nbsp;&nbsp;&nbsp;4.2 During the Term of this Agreement and not more than once during any twelve (12) month period, the Contract Price may be subject to an adjustment, provided that Supplier provides the Customer with two (2) months prior written notice of such proposed C ontract P rice adjustment a nd Customer agrees with such adjustment .

&nbsp;&nbsp;&nbsp;&nbsp;4.2 于协议期限内， 供应方 可经提前两（ 2 ）个月向买方发出书面通知 并取得买方同意后 调整合同价格，该等合同价格调整在每十二（ 12 ）个月内不得超过一（ 1 ）次。

&nbsp;&nbsp;&nbsp;&nbsp;4.3 If the Supplier's manufacturing costs rise due to increased costs (e.g., due to increased power or labor costs, increased standards on environmental protection), the Parties shall separately agree on the Contract Price change after the Customer's verification of the increased costs using information supplied by the Supplier. During the negotiation of Contract Price change, the Supplier shall provide the relevant staff salary information, power cost invoices, environmental protection expenditure information, or other supporting materials. If the Customer adjusts the Specifications or relevant requirements unilaterally, or direct the Supplier to purchase designated raw materials and packaging materials, the Contract Price shall be adjusted accordingly.

&nbsp;&nbsp;&nbsp;&nbsp;4.3 如果 供应方 的生产成本因相关成本增加（例如因能耗、人工成本增加、环境保护标准提高等原因增加），双方应在买方核实 供应方 提供的成本增加的相关信息后另行商定合同价格的变更。在双方合同价格变更沟通期间， 供应方 应提供相关人员工资信息、电费发票、环保支出信息等配套材料。如果买方要求单方变更质量标准或产品要求，或向 供应方 指定原材料、包材的采购，合同价格需相应调整。

------

Agreement No.: ANP202603001

&nbsp;&nbsp;&nbsp;&nbsp;**5.** **Supply of the Products** 

&nbsp;&nbsp;&nbsp;&nbsp;**5.** **产品供应** 

&nbsp;&nbsp;&nbsp;&nbsp;5.1 The Supplier shall promptly notify the Customer of any circumstances that result or are likely to result in any failure or delay in the supply or delivery of any Product in writing. If the Parties have a good faith belief, after mutual communication, that such circumstances may result in the failure or delay in the supply or delivery of such Product for more than ninety (90) days from the date of the Supplier's written notice, the Customer shall have the right to terminate such delivery after the full payment of costs and expenses of such Product to the Supplier.

&nbsp;&nbsp;&nbsp;&nbsp;5.1 供应方 应将任何导致或可能导致任何产品交付失败或延误的问题及时书面告知买方，双方经沟通后认为该等情形将导致 供应方 无法于供应方发出书面通知之日起九十（ 90 ）日内完成产品交付的，买方有权在支付供应方该等产品成本及费用的情况下终止该等产品的该等交付。

&nbsp;&nbsp;&nbsp;&nbsp;**6.** **Inspection of the Products** 

&nbsp;&nbsp;&nbsp;&nbsp;**6.** **产品检验** 

&nbsp;&nbsp;&nbsp;&nbsp;6.1 All Products received by the Customer will be subject to inspection and testing by the Customer, in accordance with the Customer's quality assurance program, within a period of thirty (30) days from the date of receipt of such Products ()"**Inspection Period** "). The Customer will notify the Supplier if the results of any inspection or testing indicate that the Products do not conform to the applicable Specifications or the other requirements under this Agreement. The Supplier will have ten (10) business days to respond to the Customer's notice of non-conformance. Disputes between the Parties not resolved within ten (10) business days will be resolved by an independent laboratory selected by mutual consent of the Parties. A laboratory will be appointed not later than fifteen (15) business days after the expiry of the ten (10) business day period. If the laboratory finds the Products to be nonconforming, then at the Customer's sole discretion, the Supplier shall (a) promptly deliver, at the Supplier's sole expense, the replacement Products that conform to the requirements under this Agreement, or (b) refund or credit to the Customer all payments made by the Customer with respect of such nonconforming shipment. The Customer will, at the Supplier's sole discretion, return or destroy the nonconforming Products at the Supplier's sole expense, including without limitation transportation and handling costs.

&nbsp;&nbsp;&nbsp;&nbsp;6.1 收悉产品的三十（ 30 ）天内（ "**检验期**" ），买方将根据其质量保证程序对产品质量进行检

------

Agreement No.: ANP202603001

验与测试。若检验或测试结果显示产品不符合质量标准或本协议的其他要求，买方将通知供应方。供应方应在十（10）个工作日内进行回复。若在十（10）个工作日内双方未达成一致，争议将通过经双方一致认可的独立实验室解决。双方将在上述十（10）个工作日期限届满后的十五（15）个工作日内就独立实验室的选择达成一致。若实验室检验结果仍不合格，经由买方决定，供应方应：(a)立即进行产品更换且费用自理，更换的产品应满足本协议要求；或(b)将买方就此类不合格产品支付的所有款项退还给买方或调整为对买方的应付款。经由供应方决定，买方将退回或销毁不合格产品，相关费用由供应方承担，包括但不限于运输和处理费用。

&nbsp;&nbsp;&nbsp;&nbsp;**7.** **Facility Qualification** 

&nbsp;&nbsp;&nbsp;&nbsp;**7.** **设施资质** 

&nbsp;&nbsp;&nbsp;&nbsp;7.1 The Supplier shall, take all commercially reasonable actions to qualify (and thereafter to maintain qualification of) the facility at which the Supplier Manufactures the Products, as required under Applicable Law, to enable the Customer to obtain and maintain all applicable Regulatory Dossiers in relation to the Products. The Supplier will permit the Customer and its agents, at the Customer's expense, during normal business hours and upon reasonable prior notice to the Supplier, and no more than once per year, to inspect the Facility where the Products are Manufactured, handled, stored, or tested, as well as all batch records (without making any copies) and processes relating to the Manufacture, storage, handling, or testing of the Product s and all Manufacturing, handling, storage, and test records regarding the Product s . The Supplier will respond to any non-conformances noted by the Customer, within thirty (30) business days of the written notification of such non-conformances, by submitting to the Customer a written report stating causes and corrective actions planned and providing a timetable for the correction.

&nbsp;&nbsp;&nbsp;&nbsp;7.1 供应方应根据相关法律要求，采取一切商业上合理的措施使其生产产品的设施获得（并维持）相应资质，以确保买方能够获得并维持所有与 产品 有关的监管档案。供应方应允许买方及其代理商在事先通知的情况下，在正常工作时间内对与产品生产、处理、贮存或测试相关的设施、或与产品生产、贮存、处理或测试相关的批次记录（不可复制副本）和工艺流程、以及产品的所有生产、处理、贮存或测试记录进行每年不超过一（ 1 ）次的检查，相关费用由买方承担。供应方应在收到买方的不合格书面通知后三十（ 30 ）个工作日内向买方进行回复，通过纸质报告说明不合格原因与相应改正措施，并提供改正的具体时间安排。

------

Agreement No.: ANP202603001

&nbsp;&nbsp;&nbsp;&nbsp;**8.** **Manufacturing Practices** 

&nbsp;&nbsp;&nbsp;&nbsp;**8.** **生产操作** 

&nbsp;&nbsp;&nbsp;&nbsp;8.1 The Supplier shall Manufacture the Product s in conformance with the Specifications. The Supplier shall provide the Customer with such information, including analytical and manufacturing documentation, requested by the Customer regarding quality control of the Products supplied hereunder. The Supplier will solely be responsible for keeping proper records and documentation of the manufacturing and testing of the Product s , intermediates, and starting materials, including batch records, testing records, laboratory notebooks, equipment usage, starting material batch numbers, and certifications. The Supplier will be responsible for investigating any test results or in-process testing of the Products that do not conform with the Specification. T he Supplier will conduct such laboratory investigation, which must be approved by the Supplier's quality unit, and the Supplier will promptly notify the Customer of any adverse reactions or other safety or toxicity problems known to or reasonably suspected by the Supplier regarding the Products or its use. The Supplier will promptly notify the Customer of the results of any regulatory inspection, comments, responses or notices received from the NMPA or other applicable regulatory authorities, which relate to or may impact the Manufacture and supply of the Products to the Customer.

&nbsp;&nbsp;&nbsp;&nbsp;8.1 供应方应按照质量标准进行生产，应买方书面要求，供应方应向买方提供本协议项下供应产品质量控制的相关信息，包括分析和生产文件。供应方将负责适当保存与产品、中间体和起始物料的生产与测试有关的记录和文件，包括：审批记录、测试记录、实验记录、设备使用记录、起始物料批号以及检验报告。供应方将负责调查产品发生任何不符合质量标准的测试结果或过程测试，该等调查采取实验室调查，须经供应方质量部门批准方可进行。供应方将及时通知买方针对产品已知的或合理怀疑的不良反应或其他安全或毒性问题以及自 NMPA 或其他机构收悉的可能影响产品生产及交付的检查、意见、答复或通知。

&nbsp;&nbsp;&nbsp;&nbsp;**9.** **Recall** 

&nbsp;&nbsp;&nbsp;&nbsp;**9.** **召回** 

&nbsp;&nbsp;&nbsp;&nbsp;9.1 During the Term, if either Party believes that it may be necessary to conduct a recall, field correction, market withdrawal, stock recovery, or other similar actions with respect to any Product (a "**Recall** "), the Supplier and the Customer shall consult with each other as to how best to proceed. The Parties hereby agree that the final decision as to any Recall of any such Products shall be made by the Customer; provided, however, that the Supplier will not be prohibited hereunder from taking any

------

Agreement No.: ANP202603001

action that is required by Applicable Law. The Customer shall be in charge of the Recall and establish a product recall system and recall management procedures, and the Supplier shall cooperate with the Customer as required by Applicable Law. In the event of a Recall, the Parties shall jointly find out and confirm reasons for the Recall, and except for reasonable costs borne by the Supplier if a Recall is incurred attributable to it, the Customer shall bear all costs incurred thereby.

&nbsp;&nbsp;&nbsp;&nbsp;9.1 于协议期限内，如果任一方认为有必要对任何产品进行召回、现场更正、市场撤回、库存回收或其他类似行动（ "**召回**" ），双方应协商达成最佳解决方案。双方同意，该等方案的最终决定权归买方所有，但前提是供应方也可根据相关法律要求采取相应行动。买方应当建立产品召回体系及召回管理程序，并负责召回工作，供应方在适用法律要求的范围内配合买方。产品发生召回的，由双方共同确认产品召回原因，除因供应方原因导致的产品召回由供应方承担合理费用外，任何与召回有关的费用由买方承担。

&nbsp;&nbsp;&nbsp;&nbsp;**10.** **Certificate of Analysis** 

&nbsp;&nbsp;&nbsp;&nbsp;**10.** **检验报告** 

&nbsp;&nbsp;&nbsp;&nbsp;10.1 The Supplier shall supply the same information on the certificate of analysis as is listed in the Specifications incorporated as Appendix B. No changes in Specifications will be made unless the Customer and the Supplier have agreed to such changes in writing prior to adoption of the modified Specifications.

&nbsp;&nbsp;&nbsp;&nbsp;10.1 供应方应在检验报告中提供与附录 B 中所列质量标准相同的信息。除非经双方事先书面同意，否则质量标准不得更改。

&nbsp;&nbsp;&nbsp;&nbsp;**11.** **Term, Amendment and Termination** 

&nbsp;&nbsp;&nbsp;&nbsp;**11.** **协议期限、变更、解除或终止** 

11.1This Agreement will remain in full force and effect for a period of three (5) Contract Years (the "**Term**"). Prior to the expiry of the Term, the Parties may, in their discretion, agree to extend the Term for a mutually agreed period.

11.1本协议五个合同年的期限（"**协议期限**"）内保持完全效力。在协议期限届满之前，双方可经自行决定同意将协议期限延长至双方商定的期限。

11.2During the Term, due to changes in laws and regulations, Specifications, Manufacturing procedures or other substantive conditions, this Agreement may be amended by the mutual written

------

Agreement No.: ANP202603001

consent of the Parties. Any Amendment to this Agreement and its appendices hereto shall come into force with an instrument in writing signed by the Parties.

11.2于协议期限内，因法律法规、质量标准、生产规程或其他实质性条件发生变化，经双方一致同意可对本协议进行变更，对本协议及其附录的修改，须经双方签署书面协议方能生效。

11.3Unless otherwise provided for herein, either Party (the "**Terminating Party**") may immediately terminate this Agreement by notifying the other Party (the "**Terminated Party**") in writing when one of the following situations occurs:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Terminated Party breaches this Agreement and (i) does not rectify its default within thirty (30) days on the date of receiving written notice from the Terminating Party requiring for rectification; or (ii) there is no realistic possibility to rectify such default; or (iii) such default has resulted in the inability to achieve the purpose of this Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Terminated Party suffers a Force Majeure event which makes it impossible to achieve the purpose of this Agreement ;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The Terminated Party expresses clearly or by behavior that it will not perform its obligations hereunder, or delays the performance of its obligations and has not fully performed the obligations after being notified;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) The Terminated Party loses the ability to perform its obligations hereunder, including but not limited to, entering bankruptcy proceedings, liquidation proceedings, being dissolved, being winding up, being revoked, or losing appropriate qualifications.

11.3除本协议另有约定外，任一方（"**解除方**"）可在出现下述情形之一时书面通知另一方（"**被解除**方"）立即解除本协议：

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) 被解除方违反本协议约定且 (i) 在收悉解除方书面通知要求其纠正违约行为之日起三十（ 30 ）日内未纠正其违约行为的；或 (ii) 实际上已不存在纠正违约行为的可能 ； 或 (iii) 存在违约行为导致不能实现协议目的；

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) 被解除方遭遇不可抗力且不可抗力致使不能实现协议目的；

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) 被解除方明确表示或以行为表明不履行本协议义务，或者迟延履行本协议义务且经催告后仍未全面履行的；

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) 被解除方丧失协议履行能力，包括但不限于，进入破产程序、清算程序、被解散、被注销、被吊销、丧失相应资质。

11.4This Agreement may be terminated by mutual written consent of the Parties.

------

Agreement No.: ANP202603001

11.4本协议可经由双方共同书面同意而终止。

11.5Upon expiration or termination of this Agreement, the Supplier will promptly complete and invoice for all deliverables of open and accepted purchase orders received from the Customer prior to the termination or expiration of this Agreement, and the Customer shall pay to the Supplier within thirty (30) days from the date of invoice.

11.5本协议到期或终止时，供应方应根据本协议到期或终止前已接受但未完成的买方采购订单交付产品并开具发票，买方应在供应方前述开票之日起三十（30）日内支付供应方款项。

11.6Termination or expiration of this Agreement shall not relieve either Party of any obligation accruing prior to such termination or expiration, including, without limitation, any breach of such obligation, or from any surviving obligation under this Agreement.

11.6本协议的解除、终止或到期不免除任一方在该等解除、终止或到期前产生的任何义务，包括但不限于对该等义务的任何违约，或本协议项下的任何存续义务。

11.7Either Party shall return or destroy all documents and materials in its possession which contain Confidential Information of the other Party within thirty (30) days after termination or expiration of this Agreement. The receiving party may retain one copy of documents and materials which contain the disclosing party's Confidential Information for the purpose of verifying the receiving party's compliance with its obligations under this Agreement but for no other purpose whatsoever.

11.7任何一方应在本协议解除、终止或到期后三十（30）日内归还或销毁其持有的包含另一方保密信息的所有文件和材料。接收方可以保留包含披露方保密信息的文件和材料的一份副本，以核实接收方是否遵守其在本协议项下的义务，但不得以任何其他目的。

11.8Unless otherwise provided for herein, after termination or expiration of this Agreement, section 1 (*General*), this section 11 (*Term, Amendment and Termination*), section 12 (*Intellectual Property Rights*), section 13 (*Warranties*), section 14 (*Indemnities*), section 15 (*Confidential Information*), section 16 (*Force Majeure*), section 17 (*Notices*), section 18 (*Binding Effect*), section 19 (*Governing Law and Dispute Resolution*), section20 (*Assignment*), section 21 (*Severability*), section 22 (*Entire Agreement*), section 23 (*Waiver*), section 24 (*Publicity*), section 25 (*Appendices*), section 26 (*Counterparts and Language*) shall survive.

11.8除本协议另有约定外，本协议解除、终止、到期后，本协议第1条（*总则*）、本11条（*协议期限、变更、解除或终止*）、第12条（*知识产权*）、第13条（*保证*）、第14条（*赔*

------

Agreement No.: ANP202603001

*偿*）、第15条（*保密信息*）、第16条（*不可抗力*）、第17条（*通知*）、第18条（*合同约束力*）、第19条（*管辖法律及争议解决*）、第20条（*转让*）、第21条（*可分割性*）、第22条（*完整协议*）、第23条（*弃权*）、第24条（*公开发布*）、第25条（*附录*）及第26条（*副本和语言*）仍持续有效。

&nbsp;&nbsp;&nbsp;&nbsp;**12.** **Intellectual Property Rights** 

&nbsp;&nbsp;&nbsp;&nbsp;**12.** **知识产权** 

12.1The Supplier will retain ownership of all the Supplier's Confidential Information that may be shared with the Customer during the Term of this Agreement, including retention of any manufacturing and production process for the Products (and all know-how of such process).

12.1供应方将保留在执行本协议的过程中可能与买方共享的所有供应方保密信息的所有权，包括保留任何产品的生产和制作流程（以及相应的专有技术）。

12.2The Customer will retain ownership of all Confidential Information the Customer shares with the Supplier during the Term of this Agreement.

12.2买方将保留在执行本协议过程中与供应方共享的所有买方保密信息的所有权。

&nbsp;&nbsp;&nbsp;&nbsp;**13.** **Warranties** 

&nbsp;&nbsp;&nbsp;&nbsp;**13.** **保证** 

13.1The Supplier warrants that the Products delivered to the Customer and pursuant to this Agreement shall at the time of such delivery not be adulterated or misbranded within the meaning of the Applicable Law, and that it holds all necessary intellectual property rights and licenses, filings or approvals required by all Applicable Law for the Manufacture, supply, use of the Products and/or other activities under this Agreement. The Supplier represents and warrants that it will comply with all present and future statutes, laws, ordinances and regulations relating to the Manufacture, assembly and supply of the Products being provided hereunder, including without limitation, those enforced by the NMPA.

13.1供应方保证其根据本协议所交付的产品不会因违背任何法律而被视为假药或贴错标签，并保证其拥有制造、供应、使用产品及/或开展本协议项下的其他活动所有必要的知识产权以及一切适用法律要求的许可、备案或批准。。供应方声明并保证其将遵守与本协议中产品的生产、制备和供应相关的所有现行和未来法令、法律、法规和条例，包括但不限于NMPA的法规。

------

Agreement No.: ANP202603001

13.2The Parties are not authorized to, and shall not, incur any liability for which the other Party may become directly, indirectly or contingently liable, nor shall they, except as explicitly provided in this Agreement, hold themselves out as having authority to represent or act on behalf of the other Party in any capacity whatsoever, nor shall the relationship between the Parties be construed as a co-partnership, joint venture or principal-agent relationship.

13.2双方无权也不应承担另一方可能直接、间接或偶然承担的任何责任，除非本协议有明确规定，否则双方不得以任何身份自称有权代表另一方或以另一方名义行事，双方之间的关系也不得被解释为合伙、合资或委托代理关系。

&nbsp;&nbsp;&nbsp;&nbsp;**14.** **Indemni ties** 

&nbsp;&nbsp;&nbsp;&nbsp;**14.** **赔偿** 

14.1Unless arising from the willful misconduct of the Supplier, the Customer will defend, indemnify and hold the Supplier and its Affiliates and their respective employees, servants and agents harmless against any liability, judgment, demand, action, suit, loss, damage, cost or other expense (including reasonable attorneys' fees and other costs of defense) resulting from: (i) the Customer's material breach of this Agreement or (ii) the Customer's breach of any warranty made under this Agreement.

14.1除非因供应方故意不当行为引起，当(i)买方实质性违反本协议；或(ii) 买方违反其在本协议项下的任何保证时，买方应为供应方及供应方关联方、供应方及其关联方的雇员、服务人员、代理商提供抗辩及赔偿，以使得供应方及供应方前述主体免受任何责任、判决、要求、行为、诉讼、损失、损害或费用支出（包括合理的律师费及其他辩护费用）。

14.2Unless arising from the willful misconduct of the Customer, the Supplier will defend, indemnify and hold the Customer and their Affiliates and their respective employees, servants and agents harmless against any liability resulting from any third party claims made or proceeding brought against the Customer to the extent that such liability arises from (i) the alleged or actual negligence or wilful misconduct of the Supplier; (ii) the Supplier's material breach of this Agreement; (iii) the Supplier's breach of any warranty made under this Agreement; or (iv) any infringement of any third party intellectual property rights in relation to the Products.

14.2除非因买方故意不当行为引起，当(i) 供应方存在被指称的或实际的过失或故意不当行为；(ii) 供应方实质性违反本协议；(iii) 供应方违反其在本协议项下的任何保证；或(iv) 供应方存在与产品有关的侵犯任何第三方知识产权的情形，供应方应为买方及买方关联方、

------

Agreement No.: ANP202603001

买方及其关联方的雇员、服务人员、代理商提供抗辩及赔偿，以使得买方及买方前述主体免受损害。

14.3Each indemnified party agrees to give the indemnifying party prompt written notice of any matter upon which such indemnified party intends to base a claim for indemnification (an "**Indemnity Claim**") under Section 14. The indemnifying party will have the right to participate jointly with the indemnified party in the indemnified party's defense, settlement or other disposition of any Indemnity Claim. With respect to any Indemnity Claim relating solely to the payment of money damages and which could not result in the indemnified party's becoming subject to injunctive or other equitable relief or otherwise adversely affect the business of the indemnified party in any manner, and as to which the indemnifying party will have acknowledged in writing the obligation to indemnify the indemnified party hereunder, the indemnifying party will have the sole right to defend, settle or otherwise dispose of such Indemnity Claim, on such terms as the indemnifying party, in its sole discretion, will deem appropriate, provided that the indemnifying party will provide reasonable evidence of its ability to pay any damages claimed and with respect to any such settlement will have obtained the written release of the indemnified party from the Indemnity Claim. The indemnifying party shall apply for a written release from the indemnified party prior to ceasing to defend, settling or otherwise disposing of any Indemnity Claim. If as a result thereof the indemnified party has been subject to injunctive or other equitable relief or the business of the indemnified party has been adversely affected in any matter, the application for exemption will be rejected.

14.3受偿方同意立即书面通知赔偿方，其根据本协议第14条拟提起的赔偿主张（"**赔偿主张**"）。赔偿方有权参与受偿方对任何赔偿的辩护、和解或其他方式处理赔偿主要的活动。对于任何仅与经济赔偿有关且不会导致受偿方受限于禁令或其他衡平法救济，也不会以任何形式对受偿方的业务活动产生不利影响的赔偿主张，同时赔偿方已通过书面形式确认了其在本协议项下对受偿方的赔偿义务，则赔偿方拥有以其自行认为合理的方式辩护、和解或以其他方式处理上述赔偿主张的权利，但前提是赔偿方提供合理的证据证明其有能力支付任何被主张的损害赔偿，并且就任何此类和解已获得受偿方的书面免责声明。赔偿方应在辩护、和解或其他处理方式结束之前，向受偿方申请书面免责声明，若受偿方已获得禁令、衡平法救济或其业务活动已受到不利影响，免责申请将被拒绝。

14.4Unless otherwise provided for herein, if the Customer pays the Contract Price under this Agreement which are overdue, the Supplier shall have the right to require the Customer to pay

------

Agreement No.: ANP202603001

0.05% interest of the overdue payment per day as liquidated damages.

14.4除本协议另有约定外，买方逾期支付供应方本协议项下合同价格，每逾期一天，供应方有权要求买方支付逾期付款部分的每日万分之五（0.05%）的利息作为违约金。

&nbsp;&nbsp;&nbsp;&nbsp;**15.** **Confidential Information** 

&nbsp;&nbsp;&nbsp;&nbsp;**15.** **保密信息** 

15.1The receiving party will treat as confidential and secret all information which has been or may hereafter be disclosed by the disclosing party, directly or indirectly, to the receiving party, either orally, in writing or through inspection. The receiving party shall use the Confidential Information received only to the extent necessary to execute the Purpose of this Agreement. The receiving party will not disclose to anyone any Confidential Information received from the disclosing party, and will use the same degree of care, but no less than a reasonable degree of care, to prevent the disclosure of the Confidential Information to others as it uses to prevent the disclosure of its own Confidential Information. Upon request from the disclosing party, the receiving party will promptly return to the disclosing party or destroy all drawings, data, memoranda and information in physical form relating to the Confidential Information.

15.1接收方应对披露方直接或间接以口头、书面或检查的形式提供的所有信息（保密信息）进行保密。接收方仅可在履行与本协议目的所必需的范围内使用收悉的保密信息。接收方不得向任何人披露其从披露方收悉的任何保密信息，并将采取任何可行的措施保护保密信息的保密性，程度不得低于其对自身保密内容或同样性质内容的保护，并避免泄露和非授权使用。在披露方要求下，接收方应立即向披露方返还或销毁所有与保密信息有关的图纸、数据、备忘录和实物形式的信息。

15.2Each Party agrees to keep the Confidential Information confidential, which includes (but is not limited to) not disclosing the disclosing party's Confidential Information, or any part thereof (except as otherwise may be provided herein), absent the disclosing party's prior written consent, unless required to do so by Applicable Law, act or a valid order of a court or other governing, regulatory body with authority over the receiving party ("**Required Disclosure**"); provided that the receiving party will first give reasonable written notice to the disclosing party prior to any Required Disclosure and will exercise its best efforts to obtain an order or other reliable assurance that the Confidential Information disclosed will be treated at the highest level of confidentiality. Upon receipt of notice from the receiving party of any Required Disclosure, the disclosing party may, at

------

Agreement No.: ANP202603001

the disclosing party's expense, seek to quash or restrict the disclosure of the disclosing party's Confidential Information and the receiving party will not oppose or seek to impede the disclosing party's efforts to obtain such relief.

15.2每一方同意对保密信息予以保密，包括（但不限于）不得在未经披露方书面同意（除非本协议另有规定），披露披露方提供的保密信息，除非适用法律、法令或对接收方有管辖权的法院或其他管理、监管机构的有效命令要求披露（"**必要披露**"）。前提是接收方应在任何必要披露前向披露方发出书面通知，且需尽最大努力获得法令或其他可靠保证以确保所披露的信息得到最高级别的保密处理。在收悉接收方发出的任何必要披露的通知时，披露方可在自行承担费用的情况下寻求撤销或限制对披露方保密信息的披露，接收方不得反对或阻碍披露方获得该等救济。

15.3This provision of confidentiality is not intended to grant or transfer any rights to the Confidential Information to the receiving party and does not transfer or convey any rights under a patent, trademark, copyright, or other intellectual property right to or in the Confidential Information. All Confidential Information (including all copies thereof) will at all times remain the property of the disclosing party. Further, and unless otherwise provided in this Agreement, the disclosure of Confidential Information to a receiving party does not create, and is not intended to create, any form or type of agency by and between the disclosing party and the receiving party.

15.3本保密条款无意向接收方授予或转让任何保密信息的任何权利，也无意于转让任何专利、商标、版权或其他知识产权项下的保密信息的任何权利。所有保密信息（包括其所有复印件）将始终为披露方所有。此外，除非本协议另有规定，向接收方披露保密信息并不产生，也无意在披露方和接收方之间产生任何形式或类型的代理。

15.4The receiving party agrees that its obligations hereunder are necessary and reasonable to protect the disclosing party, and expressly agrees that monetary damages would be inadequate to compensate the disclosing party for any breach of any covenant or agreement set forth herein and that, in addition to any and all other remedies available at law or in equity, the disclosing party will be entitled to seek equitable relief, including injunction and specific performance, as a remedy for any actual or threatened breach of this Agreement, and no bond or other security will be required in connection with any such equitable relief. In the event of litigation relating to this Agreement, if a court of competent jurisdiction determines that a Party has breached this Agreement, then the non-breaching party may seek recovery of its reasonable legal fees, including any appeal, in addition to any other remedies to which the non-breaching party may be entitled.

------

Agreement No.: ANP202603001

15.4接收方同意本协议项下的义务对于保护披露方均为必要且合理的，如违反本协议约定，不仅应赔偿披露方经济损失，除法律或衡平法上可获得的任何和所有其他救济之外，披露方有权针对任何实际或可能违反本协议的行为寻求衡平法救济，包括禁令和特别履行，并且无需对该等衡平法救济提供任何保函或担保。如发生与本协议有关的诉讼，如果有管辖权的法院判定一方违反了本协议，则守约方有权要求获得合理的律师费（含上诉）及采取其他补救措施。

&nbsp;&nbsp;&nbsp;&nbsp;**16.** **Force Majeure** 

&nbsp;&nbsp;&nbsp;&nbsp;**16.** **不可抗力** 

16.1If the performance by either Party of any obligation under this Agreement, other than the payment of money, is prevented or impaired by a Force Majeure event, such Party will be excused from performance so long as such situation continues to prevent or impair performance, provided the Party claiming such excuse must promptly notify the other Party of the existence, nature, duration and other details of the Force Majeure event and will at all times use reasonable efforts consistent with its normal business practices to resume a complete performance.

16.1协议双方除履行付款义务外，因不可抗力的持续造成一方无法履行协议约定的义务时，该方可免除履行义务，前提是一方应立即告知另一方不可抗力的性质、持续时间及其他具体细节，并始终依照行业惯例尽合理的商业努力以恢复协议义务的履行。

16.2In the event of a Force Majeure event, the exempting party will advise the other Party from time to time as to the progress in remedying the situation and as to the time when the exempting party expects to resume its obligations. The exempting party shall promptly inform the other Party of elimination of such Force Majeure event.

16.2不可抗力免责方应定期告知另一方补救措施的进展以及预计何时恢复履行义务。不可抗力事件结束后，免责方应立即告知另一方。

&nbsp;&nbsp;&nbsp;&nbsp;**17.** **Notices** 

&nbsp;&nbsp;&nbsp;&nbsp;**17.** **通知** 

17.1.All notices hereunder shall be in writing and shall be delivered personally, mailed by overnight delivery, registered or certified mail, postage prepaid, or given by facsimile to the following addresses of the respective Parties:

------

Agreement No.: ANP202603001

---

| | |
|:---|:---|
| &nbsp;&nbsp;**If to the Customer:**<br>**If to the Supplier:**<br>| &nbsp;&nbsp;**Address:** Amphastar Nanjing Pharmaceuticals, Inc.<br>[\*\*\*] <br>**Attn: [\*\*\*]**<br>**Post Code:** [\*\*\*]<br>**Address: Nanjing Letop Biotechnology Co., Ltd.** <br>[\*\*\*]<br>**Attn:[\*\*\*]**<br>**Post Code:** [\*\*\*]<br>|

---

17.1.本协议项下的所有通知均采用书面形式，应通过亲自递送、隔夜递送、挂号信、预付邮资或传真方式发送至双方的地址，具体如下：

**买方**：**美药星（南京）制药有限公司**

地址：[\*\*\*]

联系人：[\*\*\*]

邮箱：[\*\*\*]

**供应方：南京乐韬生物科技有限公司**

地址：[\*\*\*]

联系人：[\*\*\*]

邮编：[\*\*\*]

&nbsp;&nbsp;&nbsp;&nbsp;**18.** **Binding Effect** 

&nbsp;&nbsp;&nbsp;&nbsp;**18.** **合同约束力** 

18.1.This Agreement shall be binding upon and inure to the benefit of the Parties and their respective assigns and successors in interest.

18.1.本协议将对双方及其各自的受让人和利益继承人具有约束力并及于其各自之利益。

&nbsp;&nbsp;&nbsp;&nbsp;**19.** **Governing Law and Dispute Resolution** 

&nbsp;&nbsp;&nbsp;&nbsp;**19.** **管辖法律及争议解决** 

19.1The Agreement shall be construed, interpreted and governed by the laws of the PRC.

19.1本协议应受中国法律管辖并解释。

------

Agreement No.: ANP202603001

19.2This Agreement and any dispute or claim arising out of or in connection with it or its subject matter or formation (including non-contractual disputes or claims) (the "**Disputes**") shall first be resolved through consultation. If the Disputes cannot be resolved through negotiation, the Dispute (including a Dispute in connection with the validity or continuity of this Agreement) shall be submitted to arbitration in Shanghai under the auspices of the Shanghai International Economic and Trade Arbitration Commission with its then effective arbitration rules. The arbitration tribunal shall be consisted by three (3) members. One (1) arbitrator shall be appointed by the Party initiating the arbitration, one (1) arbitrator shall be appointed by the other Party, and the third arbitrator shall be jointly selected by the two (2) appointed arbitrators.

19.2本协议以及因本协议及其内容或成立而引起的或与之相关的任何争议或诉请（包括非合同争议或诉请）（以下简称"**争议**"）应由双方通过友好协商解决。如不能通过协商解决的，则该争议（包括有关本协议有效性或存续性的争议）应提交上海国际经济贸易仲裁委员会，按照其届时有效的仲裁规则在上海进行仲裁。仲裁庭由三（3）名成员组成。其中一（1）名仲裁员由提起仲裁方指定，一（1）名仲裁员由答辩方指定，第三名仲裁员由该两名仲裁员共同选定。

19.3The award of the arbitration tribunal shall be final and binding upon the Parties, and each Party may apply to a court of competent jurisdiction for enforcement of such award. Except for matters in the Dispute during a Dispute which is being resolved in accordance with this Agreement, the Parties shall continue to perform their obligations hereunder.

19.3仲裁裁决应为终局的，对双方均具有约束力，并可根据有关条款规定强制执行。在按照本协议约定解决争议期间，除争议所涉事项外，双方应继续履行其在本协议项下的义务。

&nbsp;&nbsp;&nbsp;&nbsp;**20.** **Assignment** 

&nbsp;&nbsp;&nbsp;&nbsp;**20.** **转让** 

20.1Neither Party shall assign or transfer its rights and obligations hereunder to any other party without the prior written consent of the other Party. Notwithstanding the foregoing, this Agreement and the rights and obligations herein may be assigned by each Party to any of its Affiliate, and either Party, may assign or sell the same in connection with the transfer or sale of substantially its entire business to which this Agreement pertains or in the event of its merger or consolidation with another company without such consent. Any permitted assignee will assume all obligations of its

------

Agreement No.: ANP202603001

assignor under this Agreement.

20.1未经另一方事先书面同意，任何一方均不得转让本协议。尽管有前述约定，一方可将其本协议项下权利义务转让给其关联方，且一方转让或出售其与本协议有关的绝大部分业务或与另一家公司合并时转让本协议则无需征得另一方同意。任一获准受让人应承担其转让人在本协议项下的所有义务。

20.2No assignment will relieve any Party of the responsibility for the performance of any obligation hereunder.

20.2任何形式的转让都不会免除任何一方履行本协议项下任何义务的责任。

&nbsp;&nbsp;&nbsp;&nbsp;**21.** **Severability** 

&nbsp;&nbsp;&nbsp;&nbsp;**21.** **可分割性** 

21.1.In the event that any term or provision of this Agreement is held invalid or unenforceable by a court of competent jurisdiction, the remaining terms shall be valid and enforced to the fullest extent permitted by Applicable Law. If any term or provision of this Agreement is deemed by a court to be unenforceable because such provision is too broad in scope, the provision shall be construed in a limited scope to make it enforceable.

21.1.若本协议的任何条款或约定被有管辖权的法院认定为无效或不可强制执行，其余条款将在适用法律允许的最大范围内有效并可强制执行。如果本协议的任何条款或约定因适用范围过宽而被法院认定为不可强制执行，则该条款将在有限范围内进行解释以使其具有可强制执行性。

&nbsp;&nbsp;&nbsp;&nbsp;**22.** **Entire Agreement** 

&nbsp;&nbsp;&nbsp;&nbsp;**22.** **完整协议** 

22.1.This Agreement constitutes the entire agreement between the Parties concerning the subject matter and supersedes all prior agreements or understandings between the Parties.

22.1.本协议构成双方之间关于就本协议主题事项的全部约定，并取代双方之前所有的约定或谅解。

&nbsp;&nbsp;&nbsp;&nbsp;**23.** **Waiver** 

&nbsp;&nbsp;&nbsp;&nbsp;**23.** **弃权** 

------

Agreement No.: ANP202603001

23.1.No waiver or modification of any of the terms of this Agreement shall be valid unless in writing and signed by authorized representatives of both Parties. Failure by either Party to enforce any rights under this Agreement shall not be construed a waiver of any rights, nor will a waiver by a Party in one instance be construed as a continuing waiver or a waiver in other instances.

23.1.除非由双方授权代表书面签署，否则对本协议任何条款的放弃或修改均无效。任何一方未能行使本协议项下的权利不应被解释为在该情况下或任何其他情况下放弃此类权利。任何一方在某种情况下的弃权也不应被解释为持续性弃权或视为在其它情况下的弃权。

&nbsp;&nbsp;&nbsp;&nbsp;**24.** **Publicity** 

&nbsp;&nbsp;&nbsp;&nbsp;**24.** **公开发布** 

24.1.Other than as required by Applicable Law, in the absence of specific agreement between the Parties, neither Party shall originate any publicity, news release or other public announcement, written or oral, whether to the public press, to stockholders or otherwise relating to this Agreement.

24.1.除适用法律要求外，在双方间无具体协议或约定的情况下，任何一方不得向公众媒体、股东或以其他方式发起与本协议相关的任何书面或口头的宣传、新闻发布或其他公告。

&nbsp;&nbsp;&nbsp;&nbsp;**25.** **Appendices** 

&nbsp;&nbsp;&nbsp;&nbsp;**25.** **附录** 

25.1.All appendices referenced herein are made a part of this Agreement.

25.1.本协议中所有附录均构成本协议的一部分。

&nbsp;&nbsp;&nbsp;&nbsp;**26.** **Counterparts and Language** 

&nbsp;&nbsp;&nbsp;&nbsp;**26.** **副本和语言** 

&nbsp;&nbsp;&nbsp;&nbsp;26.1. This Agreement may be executed in several duplicates, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. For the avoidance of doubt, this Agreement is concluded both in Chinese version and English version. In the event of any discrepancy between the Chinese version and the English version, the English version shall prevail.

&nbsp;&nbsp;&nbsp;&nbsp;26.1. 本协议可签署多份副本，每一份副本均应被视为原件，且所有副本应共同构成同一文件。为避免疑义，本协议以中文和英文书就。若中文版本和英文版本之间存在不一致之处，应以英文版本为准。

------

Agreement No.: ANP202603001

**In Witness whereof**, the Parties have executed this Agreement by their duly authorized representatives.

*兹证明，双方已由其正式授权代表签署本协议。*

---

| | | | |
|:---|:---|:---|:---|
| Amphastar Nanjing Pharmaceuticals, Inc.<br>美药星（南京）制药有限公司 | Amphastar Nanjing Pharmaceuticals, Inc.<br>美药星（南京）制药有限公司 | Nanjing Letop Biotechnology Co., Ltd.<br>南京乐韬生物科技有限公司 | Nanjing Letop Biotechnology Co., Ltd.<br>南京乐韬生物科技有限公司 |
| By/签署: | /s/Qiu Yinhua | By/签署: | /s/Xu Yonggang |
| Name/姓名: | 邱银华 Qiu Yinhua | Name/姓名: | 徐勇刚 Xu Yonggang |
| Title/职位: | 总经理 General Manager | Title/职位: | 总经理 General Manager |
| Date/日期: | March 3, 2026 | Date/日期: | March 3, 2026 |

---

------

Agreement No.: ANP202603001

#### APPENDIX A: PRODUCTS AND CONTRACT PRICE

#### 附录 A ：产品及合同价格
[\*\*\*]

------

Agreement No.: ANP202603001

#### APPENDIX B : SPECIFICATIONS

#### 附录 B ：质量标准
[\*\*\*]

------

## Exhibit 10.2

**Exhibit 10.2**

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([\*\*\*]), HAS BEEN OMITTED PURSUANT TO ITEM 601(B)(10)(IV) OF REGULATION S-K, BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. IN ADDITION, CERTAIN SCHEDULES (OR SIMILAR ATTACHMENTS) HAVE BEEN OMITTED FROM THIS EXHIBIT PURSUANT TO ITEM 601(A)(5) OF REGULATION S-K.

ConAmendment No.: 1

**AMENDMENT TO CONTRACT RESEARCH AGREEMENT**

**委托开发协议增补协议**

This First Amendment (the "**First Amendment**") to the Contract Research Agreement by and between Amphastar Pharmaceuticals, Inc., a company established and existing in accordance with the laws of the State of Delaware, the United States of America, on behalf of itself and its Affiliates (together with its Affiliates, the "**Customer**") and Nanjing Hanxin Pharmaceutical Technology Co., Ltd., a limited liability company duly incorporated and validly existing under the laws of PRC, with the Unified Social Credit Code: [\*\*\*] ("**HX**") dated September 15, 2025 (the "**Agreement**"), is hereby made as of March 3, 2026, by and between the Customer and HX. Any capitalized terms not defined herein shall maintain the same meaning as prescribed to it in the Agreement.

本第一次增补协议（"**第一次增补协议**"）系对由Amphastar Pharmaceuticals, Inc.，一家根据美国特拉华州法律成立并存续的公司（与其关联方合称为"**委托方**"）和南京汉欣医药科技有限公司，一家根据中国法律正式成立并有效存续的有限责任公司，统一社会信用代码为：[\*\*\*]（"**HX**"）于2025年9月15日签订的委托开发协议（"**原协议**"）的增补修订，特此于2026年3月3日由委托方和HX签署。本第一次增补协议中未定义的大写术语均保持原协议中规定的相同含义。

**WHEREAS**, the Customer and HX have previously entered into the Agreement, pursuant to which the Parties mutually agree that the Customer engages HX to research and develop certain active pharmaceutical ingredients;

鉴于，委托方和HX之前已签订原协议，根据原协议的约定，双方一致同意委托方委托HX研发某些活性药物成分；

**WHEREAS**, the Parties intend to change the product and relevant terms and conditions under the Agreement;

鉴于，双方拟对原协议项下产品及相关条款进行变更；

**WHEREAS**, the Customer and HX have determined it to be mutually beneficial to amend the Agreement subject to the terms set forth herein;

鉴于，委托方和HX已确定根据本第一次增补协议的条款修订原协议符合双方共同利益；

**NOW THEREFORE**, in consideration of the mutual covenants set forth herein, the

------

receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree to amend and supplement the Agreement as follows:

因此，鉴于双方已确认收到并认可的本第一次增补协议中所述的相互承诺，双方特此同意对原协议进行如下增补：

&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Recitals</u>. The recitals contemplated above are incorporated by reference as if fully stated herein.

&nbsp;&nbsp;&nbsp;&nbsp;2. <u>Amendment to Section 1.3(</u> <u>k</u> <u>) ("</u> <u>Product</u> <u>")</u>. The Parties mutually agree to amend the definition of "Product" under Section 1.3(k) on page 6 of the Agreement by deleting it in its entirety and replacing it with the following language:

<u>对第</u><u>1.3(</u><u>k</u><u>)</u><u>条（</u><u>"</u><u>产品</u><u>"</u><u>）的修订</u>。双方一致同意修订原协议第6页第1.3(k)条中"产品"的定义，将其整体删除并替换为以下表述：

"'Product' means [\*\*\*]

&nbsp;&nbsp;&nbsp;&nbsp;3. <u>Amendment to Section</u> <u>5</u> <u>(</u> <u>Payment</u> <u>)</u>. The Parties mutually agree to amend Section 5 of the Agreement by deleting it in its entirety and replacing it with the following language:

<u>对第</u><u>5</u><u>条（</u><u>付款</u><u>）的修订</u>。双方一致同意修订原协议第5条，将其整体删除并替换为以下表述：

"5.1 As of the Effective Date of the Agreement, HX acknowledges, agrees and confirms that the Customer has paid HX CNY 2,000,767.

"5.1 委托方已于原协议生效日向HX支付人民币2,000,767元。

&nbsp;&nbsp;&nbsp;&nbsp;5.2 The Parties acknowledge that HX has undertaken works on the original "Product" specified in the Agreement (prior to the amendment in the First Amendment, the "**Original Product**") in accordance with the terms of the Agreement. The Customer agrees to pay HX: (i) CNY [\*\*\*] for the works HX has completed on the Original Product; and (ii) CNY [\*\*\*] for the 20-gram sample of the Original Product that HX has produced as requested by the Customer (item (i) and (ii) collectively, the "**Original Product Payment**"). The Parties agree that the Original Product Payment shall be deducted from the payment made by the Customer under Section 5.1 above. Other than the Original Product Payment, the Customer shall have no obligation to pay for any work performed by HX in relation to the Original Product.

&nbsp;&nbsp;&nbsp;&nbsp;5.2 双方认可，HX根据原协议的约定已就原协议定义的产品（尚未根据第一次增补协议修订前的产品，"**原产品**"）开展工作。委托方同意向HX支付：(i) 就HX针对原产品已开展的工作，支付人民币[\*\*\*]元；(ii) 就

------

HX根据委托方的要求已生产的20克原产品的样品，支付人民币[\*\*\*]元（第(i)项及第(ii)项合称"**原产品费用**"）。双方同意，原产品费用应从上述第5.1条项下委托方已支付的款项中扣除。除原产品费用外，委托方无义务就HX基于原产品开展的任何工作支付费用。

&nbsp;&nbsp;&nbsp;&nbsp;5.3 The Customer shall make the following payments to HX with respect to HX's performance of the Scope of Works for the Product (after the amendment in the First Amendment):

&nbsp;&nbsp;&nbsp;&nbsp;5.3 就HX对产品（根据第一次增补协议修订后的产品）相关工作范围的履行而言，委托方应向HX支付下列款项：

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) HX shall submit to the Customer an invoice and provide the Customer with all evidential documents related to the payment at the end of each calendar quarter, and the Customer shall make payment within thirty (30) days after receipt of such invoice and inspection of all relevant evidential documents; provided however that, if the Customer disagrees with any part of the invoice, the Customer will notify HX in writing, noting its objection to the disputed item(s) with specificity within ten (10) Business Days upon receipt of the invoice and evidential documents, and pay the undisputed portion in accordance with the aforementioned period, and the Parties shall discuss and agree in good faith the remaining unpaid amount as soon as possible. The non-payment of any items disputed in good faith hereunder shall not constitute a breach of this Agreement, and HX shall not suspend the performance of services due to such non-payment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) HX 应在每个公历季度末向委托方提交发票，并向委托方提供与付款相关的所有证明文件，委托方应在收悉该等发票并验证所有相关证明文件之日起三十（ 30 ）日内付款；如委托方对发票的任何部分有异议，委托方将在收到发票和证明文件后的十（ 10 ）个工作日内书面通知 HX ，指明其对争议事项的具体异议，并根据前述期限支付无争议部分的款项，双方应尽快善意讨论剩余未付金额并就此达成一致。根据本条对于任何善意争议款项的不予支付不应构成委托方对本协议的违反，且 HX 不得因该等未支付行为而中止提供服务。

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Total payment made from the Customer to HX shall not exceed CNY [\*\*\*] (Payment from the Customer to HX will be adjusted from CNY to USD, based on actual currency exchange rate as reported by the Bloomberg Currency Spot Exchange Rate the date of which the invoice is issued by HX).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) 委托方向 HX 支付的总金额不得超过人民币 [\*\*\*] 元（委托方向 HX 支付的款项将从人民币调整为美元，以 HX 发票开具之日公布的彭博货币即期汇率的实际货币兑换率计算）。

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Any additional work or changes to the Scope of Work that the Customer is requesting from HX will be charged by HX to the Customer in the amount equal

------

to the sum of (i) HX's direct costs for such additional work, plus (ii) [\*\*\*]% of the amount of such direct costs plus any applicable taxes. Any additional cost must be provided to the Customer for approval prior to the work being performed."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) 委托方要求 HX 进行的任何额外工作或对工作范围的变更将由 HX 向委托方收取金额相当于如下各项之和的款项： (i) HX 开展该等额外工作的直接支出，加上 (ii) 该等直接支出的 [\*\*\*] % 再加上任何适用的税款。任何额外费用必须在开展工作前提供予委托方供批准。 "

&nbsp;&nbsp;&nbsp;&nbsp;4. <u>Governing Law and Dispute Resolution</u>. Section 14 (Governing Law and Dispute Resolution) of the Agreement shall, *mutatis mutandis*, apply to this First Amendment.

<u>管辖法律及争议解决</u>。原协议第14条（管辖法律及争议解决）应经必要调整后适用于本第一次增补协议。

&nbsp;&nbsp;&nbsp;&nbsp;5. <u>Effectiveness</u>. This First Amendment will take effect as of the date executed by both Parties.

<u>效力</u>。本第一次增补协议自双方签署之日起产生效力。

&nbsp;&nbsp;&nbsp;&nbsp;6. <u>Entire Agreement</u>. This First Amendment, together with the Agreement, constitutes the entire agreement of the Parties hereto with respect to the subject matter of the Agreement and supersedes all prior agreements, understanding, promises and representations, whether written or oral, with respect to the subject matter thereof.

<u>完整协议</u>。本第一次增补协议连同原协议构成双方之间关于原协议主题事项达成的完整协议，并取代双方此前就该主题事项达成的所有书面或口头的协议、理解、承诺及陈述。

&nbsp;&nbsp;&nbsp;&nbsp;7. <u>No Further Modification</u>. Except as expressly and specifically amended hereby, all other provisions, terms and conditions of the Agreement shall remain unchanged, and in full force and effect.

<u>无其他修订</u>。除本第一次增补协议明确且具体修订的内容外，原协议中所有其他条款和条件均保持不变，并继续完全有效。

&nbsp;&nbsp;&nbsp;&nbsp;8. <u>Counterparts</u>. This First Amendment may be executed by facsimile (including a PDF image delivered via e-mail) or electronically transmitted signatures and such signatures shall be deemed to bind each Party hereto as if they were original signatures. This First Amendment may be executed in counterparts, each of which shall be deemed to be an original, and which together will constitute one original.

------

<u>副本</u>。本第一次增补协议可通过传真（包括通过电子邮件发送的PDF图像）或电子传输签名的方式签署，此类签名应被视为与原始签名一样对各方具有约束力。本第一次增补协议可签署成若干副本，每份副本均应视为正本，且所有副本共同构成一份正本。

*[Signature Page Follows]*

*[以下为签署页]*

------

**IN WITNESS WHEREOF**, the Parties have executed this Agreement by their duly authorized representatives.

有鉴于此，本第一次增补协议由双方授权代表正式签署。

---

| | | | |
|:---|:---|:---|:---|
| **Amphastar Pharmaceuticals, Inc.** | **Amphastar Pharmaceuticals, Inc.** | **Nanjing Haxin Pharmaceutical Technology Co., Ltd.**<br>**南京汉欣医药科技有限公司** | **Nanjing Haxin Pharmaceutical Technology Co., Ltd.**<br>**南京汉欣医药科技有限公司** |
| By/签署: | /s/Jacob Liawatidewi | By/签署: | /s/Bao Haitao |
| Name/姓名: | Jacob Liawatidewi | Name/姓名: | 鲍海涛Bao Haitao |
| Title/职位: | EVP Corporate Administration | Title/职位: | General Manager |
| Date/日期: | March 3, 2026 | Date/日期: | March 3, 2026 |

---

------